The Scripps Research Institute

National Research Council of Canada

Roche Innovation Center Copenhagen A/s

Astrazeneca Canada Inc.

Astrazeneca Ab

Santaris Pharma A/s

Astra Pharma Inc.

Claes Wahlestedt

Philippe Walker

Troels Koch

Sultan Ahmad

Shi-Hsiang Shen

Zicai Liang

Henrik Orum

Edward Roberts

Joacim Elmén

Niklas Plobeck

Ahmad Sultan

Anders M Sorensen

Shen Shi-Hsiang

Thomas D Bannister

Henrik Ørum

Hasib Salah-Uddin

Xiaohong Pan

Joachim Elmén

Yen Ting Chen

Anders Malling Sørensen

Shaun P Brothers

Small interfering RNA (siRNA) knock down antisense transcripts, and regulate the expression of their sense partners. This regulation can either be discordant (antisense knockdown results in sense transcript elevation) or concordant (antisense knockdown results in concomitant sense transcript reduction).

Natural antisense and non-coding RNA transcripts as drug targets

The present invention is directed to novel double-stranded short interfering (siRNA) analogs comprising locked nucleic acid (LNA) monomers. Such compounds induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). The compounds disclosed herein has improved properties compared to non-modified siRNAs and may, accordingly, be useful as therapeutic agents, e.g., in the treatment of various cancer forms. More particularly, the present invention is directed to siRNA analogs comprising a sense strand and an antisense strand, wherein each strand comprises 12-35 nucleotides and wherein the siRNA analogs comprise at least one locked nucleic acid (LNA) monomer.

Short interfering RNA (siRNA) analogues

The invention provides modulators of the nociceptin receptor (NOP), including both agonists and antagonists. A compound of the invention can be a selective modulator of NOP with respect to the &#x3bc;- and &#x3ba;-opioid receptors (MOP and KOP), thus providing a therapeutic method for the treatment of conditions wherein selective NOP modulation is medically indicated and MOP or KOP modulation may be less desirable. A compound of the invention can be a NOP full agonist, partial agonist, inverse agonist, positive or negative allosteric modulator, or a functionally biased agonist. A compound of the invention can be used for the treatment of an anxiety state, post-traumatic stress disorder, addictive disorders (including overuse of alcohol, tobacco, and drugs of abuse such as cocaine, amphetamines, and opitates), misregulated food intake and/or energy expenditure, cough, sleep disorders, migraine, pain, depression, or neurodegenerative disorders such as Parkinsons disease or Alzheimers disease.

Substituted benzimidazoles as nociceptin receptor modulators

The present invention is directed to novel double-stranded short interfering (siRNA) analogues comprising locked nucleic acid (LNA) monomers. Such compounds induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). The compounds disclosed herein has improved properties compared to non-modified siRNAs and may, accordingly, be useful as therapeutic agents, e.g., in the treatment of various cancer forms. More particularly, the present invention is directed to siRNA analogues comprising a sense strand and an antisense strand, wherein each strand comprises 12-35 nucleotides and wherein the siRNA analogues comprise at least one locked nucleic acid (LNA) monomer.

The present invention is directed to a novel receptor for galanin which has been designated as galanin receptor 2. The invention encompasses both the receptor protein as well as nucleic acids encoding the protein. In addition, the present invention is directed to methods and compositions which rely upon either GAL-R2 proteins or nucleic acids.

Isolated human and rat GAL-R2 galanin receptors

Assay employing human or rat GAL-R2 galanin receptor

The present invention is directed to methods for assaying a test compound's ability to alter the expression of novel receptor for galanin which has been designated as galanin receptor 2. The invention also encompasses both the receptor protein as well as nucleic acids encoding the protein. In addition, the present invention is directed to additional methods and compositions which rely upon either GAL-R2 proteins or nucleic acids.

Methods for assaying expression of novel galanin receptors

The present invention is directed to galanin receptor 2 (GAL-R2) proteins and nucleic acids.

Galanin receptor 2 proteins and nucleic acids

Compounds with analgesic effect

Galanin receptor

Growing community of inventors

Stockholm, Sweden

Claes Wahlestedt